stoxline Quote Chart Rank Option Currency Glossary
Adaptive Biotechnologies Corporation (ADPT)
4.04  0.16 (4.12%)    02-23 16:00
Open: 3.87
High: 4.0762
Volume: 1,123,480
Pre. Close: 3.88
Low: 3.7868
Market Cap: 585(M)
Technical analysis
2024-02-23 4:34:47 PM
Short term     
Mid term     
Targets 6-month :  5.24 1-year :  6.12
Resists First :  4.48 Second :  5.24
Pivot price 3.78
Supports First :  3.82 Second :  3.41
MAs MA(5) :  3.88 MA(20) :  3.81
MA(100) :  4.38 MA(250) :  6.1
MACD MACD :  -0.1 Signal :  -0.2
%K %D K(14,3) :  60.6 D(3) :  55.1
RSI RSI(14): 51.8
52-week High :  9.17 Low :  2.6
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ADPT ] has closed below upper band by 9.3%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.08 - 4.1 4.1 - 4.11
Low: 3.75 - 3.77 3.77 - 3.78
Close: 4.01 - 4.04 4.04 - 4.07
Company Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Headline News

Sun, 25 Feb 2024
Adaptive Biotechnologies: A Post Earnings Assessment (NASDAQ:ADPT) - Seeking Alpha

Thu, 22 Feb 2024
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference - GlobeNewswire

Sat, 17 Feb 2024
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically - Simply Wall St

Thu, 15 Feb 2024
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript - Yahoo Finance

Wed, 14 Feb 2024
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewswire

Wed, 14 Feb 2024
Adaptive Biotechnologies Corp (ADPT) Faces Revenue Decline Amid Growth in MRD Segment - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 145 (M)
Shares Float 99 (M)
Held by Insiders 1.7 (%)
Held by Institutions 98 (%)
Shares Short 8,810 (K)
Shares Short P.Month 9,460 (K)
Stock Financials
EPS -1.37
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.13
Profit Margin -132.3 %
Operating Margin -99.7 %
Return on Assets (ttm) -16.7 %
Return on Equity (ttm) -58.4 %
Qtrly Rev. Growth -17.2 %
Gross Profit (p.s.) 0
Sales Per Share 1.17
EBITDA (p.s.) -1.24
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -2.98
PEG Ratio -0.2
Price to Book value 1.89
Price to Sales 3.43
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android